Abstracts tagged "Fibroblasts"

Abstract Number: 1131 • 2016 ACR/ARHP Annual Meeting
Regulation of Rheumatoid Arthritis Synovial Fibroblast Cytokine Production By Inhibitor of DNA Binding-1 Via Crispr/Cas9 Transfection
Ray A. Ohara¹, Gautam Edhayan¹, Thomas L. Saunders², Thomas M. Lanigan³, Rachel Morgan¹, W. Alexander Stinson⁴, Phillip L. Campbell⁵, Jerry Graham⁴, David A. Fox⁵ and Jeffrey H. Ruth⁵, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Molecular Medicine and Genetics, University of Michigan Medical School, Ann Arbor, MI, ³Vector Core, University of Michigan Medical School, Ann Arbor, MI, ⁴Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Inhibitor of DNA binding-1 (Id1) is a nuclear protein actively transcribed in endothelial progenitor cells (EPCs) and synovial fibroblasts. We previously identified Id1 as…
Abstract Number: 3146 • 2016 ACR/ARHP Annual Meeting
Selective Deletion of a Pathogenic Subset Synovial Fibroblasts Attenuates Synovial Inflammation
Adam Paul Croft, Joana Campos, Andrew Filer, Francesca Barone and Chris Buckley, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Despite their role as key effector cells driving synovial inflammation and joint damage, fibroblast like synoviocytes (FLS) have yet to be targeted therapeutically. Fibroblast…
Abstract Number: 1435 • 2016 ACR/ARHP Annual Meeting
KCa1.1 Potassium Channels Are a Novel Therapeutic Target on Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Mark Tanner¹, Redwan Huq¹, Rajeev Tajhya¹, Michael Pennington², Teresina Laragione³, Pércio Gulko⁴ and Christine Beeton⁵, ¹Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX, ²Peptides International, Louisville, KY, ³Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX
Background/Purpose: Fibroblast-like synoviocytes (FLS) develop a high degree of invasiveness during rheumatoid arthritis (RA), leading to joint degradation. There are currently no therapeutics that specifically…
Abstract Number: 3178 • 2016 ACR/ARHP Annual Meeting
Heart Dysfunction in Systemic Sclerosis: Involvement of a Novel Fibrogenic Stromal Cell Subset
Mara Stellato¹, Michal Rudnik¹, Florian Renoux², Elena Pachera¹, Karl Sotlar³, Karin Klingel⁴, Joerg C. Henes⁵, Przemyslaw Blyszczuk⁶, Oliver Distler¹ and Gabriela Kania¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Depertment of Rheumatology, University Hospital Zurich, Schlieren, Switzerland, ³Institute of Pathology, Ludwig Maximilians University, Munich, Germany, ⁴Department of Molecular Pathology, University Hospital Tuebingen, Tuebingen, Germany, ⁵Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ⁶Cardioimmunology, Center of Molecular Cardiology, University of Zurich, 8952 Schlieren, Switzerland
Background/Purpose: Cardiac dysfunction is a significant cause of the high mortality in systemic sclerosis (SSc). Heart involvement in SSc patients resembles inflammatory dilated cardiomyopathy (iDCM)…
Abstract Number: 1558 • 2016 ACR/ARHP Annual Meeting
Lower Expression of a Novel Cytoplasmic Long Noncoding RNA NR_122076 Contributes to Proliferation, Migration and Invasion of Fibroblast-like Synoviocytes from Patients with Rheumatoid Arthritis
Yaoyao Zou, Siqi Xu, Qian Qiu, Shan Zeng, Maohua Shi, Youjun Xiao, Mingcheng Huang and Hanshi Xu, Department of Rheumatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China., Guangzhou, China
Background/Purpose: Emerging evidence indicates that long noncoding RNAs (lncRNAs) play critical regulatory roles in various human diseases, especially in cancers and inflammatory disorders. However, the…
Abstract Number: 3215 • 2016 ACR/ARHP Annual Meeting
ASK1 Is Regulated By IL-1β and TNF and Modulates Key Rheumatoid Arthritis (RA) Fibroblast-like Synoviocyte Functions (FLS)
Gyrid Nygaard¹, Deepa Hammaker², David L. Boyle³, Astrid Clarke⁴, Li Li⁵, Julie Dipaolo⁶ and Gary Firestein⁷, ¹Medicine, UC San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ⁴GIlead, South San Francisco, CA, ⁵Gilead Sciences, South San Francisco, CA, ⁶Gilead, South San Francisco, CA, ⁷Medicine, UCSD, La Jolla, CA
Background/Purpose: RA fibroblast-like synoviocytes (FLS) possess a unique aggressive phenotype characterized by increased cell growth, cytokine production and invasion. Previous unsuccessful attempts to target the…
Abstract Number: 1564 • 2016 ACR/ARHP Annual Meeting
The Comprehensive Analysis for the Transcriptional Organization of Stimuli Responses in Fibroblast-like Synoviocytes from Rheumatoid Arthritis Patients
Haruka Tsuchiya¹, Shuji Sumitomo¹, Kazuyoshi Ishigaki², Akari Suzuki², Yuta Kochi², Mineto Ota¹, Yumi Tsuchida¹, Hiroshi Inui³, Shuji Taketomi³, Yuho Kadono⁴, Sakae Tanaka³, Keishi Fujio¹ and Kazuhiko Yamamoto^1,2, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ³Department of Orthopaedic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Department of Orthopaedic Surgery, Graduate School of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Fibroblast-like synoviocyte (FLS) is expected to be a novel therapeutic target for rheumatoid arthritis (RA) because of their contribution to pathogenesis. FLS expresses…
Abstract Number: 1661 • 2016 ACR/ARHP Annual Meeting
Toll-like Receptor 4 Induced IL-20 and IL-24 Stimulate Osteoblast Mineralization and Are Increased in Spondyloarthritis
Tue Wenzel Kragstrup^1,2, Morten Nørgaard Andersen³, Berit Schiøttz-Christensen⁴, Anne Grethe Jurik⁵, Malene Hvid⁶ and Bent Deleuran¹, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark, ⁴Hospital Lillebaelt, Middelfart, Denmark, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: The pathogenesis of spondyloarthritis (SpA) involves activation of the innate immune system, inflammation and new bone formation. The innate immune system is activated through…
Abstract Number: 1671 • 2016 ACR/ARHP Annual Meeting
Pirfenidone Might Inhibit New Bone Formation in Spondyloarthritis: Proof of Concept Study Using Cell Culture Models
Julie Laustsen¹, Søren Lomholt¹, Pernille Andersen², Jens Kelsen³ and Tue Wenzel Kragstrup^1,4, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Interdisciplinary Nanoscience Center, Aarhus University, Aarhus, Denmark, ³Department of Gastroenterology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: The pathogenesis of spondyloarthritis (SpA) involves both inflammation and new bone formation in the spine. In line with this, the disease has been characterized…
Abstract Number: 1852 • 2016 ACR/ARHP Annual Meeting
Decreased Expression of Sirtuin 7 By Lung Fibroblasts from Patients with Scleroderma Contributes to Elevated Collagen Production
Anne E. Wyman^1,2, Zahid Noor¹, Nevins W. Todd^1,2, Irina G. Luzina^1,2 and Sergei P. Atamas^1,2, ¹University of Maryland School of Medicine, Baltimore, MD, ²Baltimore VA Medical Center, Baltimore, MD
Background/Purpose: Pulmonary fibrosis is a severe complication of systemic sclerosis (SSc). Changes in the expression levels of sirtuins (SIRTs), a family of NAD+-dependent histone deacetylases,…
Abstract Number: 1855 • 2016 ACR/ARHP Annual Meeting
Phosphodiesterase-5 Inhibitors Attenuate Fibrotic Phenotype and Restore Anti-Fibrotic Resopnses of Cutaneous Fibroblasts in Patients with Scleroderma
Vikas Agarwal¹, Mohit kumar Rai¹, Vinita Agrawal², Harshit Singh¹ and Saurabh Chaturvedi¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India
Background/Purpose: Scleroderma (SSc) is a chronic autoimmune disease, characterized by excessive fibrosis of skin and internal organs due to uncontrolled proliferation of fibroblasts and deposition…
Abstract Number: 1857 • 2016 ACR/ARHP Annual Meeting
A Novel Highly Selective 5-Hydroxytryptamine 2B (5-HT2B) Receptor Antagonist Ameliorating Fibrosis in Preclinical Models of Systemic Sclerosis
Christina Wenglén¹, Lars Pettersson², Helena Arozenius² and Gunilla Ekström¹, ¹R&D, AnaMar AB, Lund, Sweden, ²AnaMar AB, Lund, Sweden
Background/Purpose: Methods: Results: Conclusion: The results demonstrate that the 5-HT2B receptor antagonist AM1125 prevents pro-fibrotic events in human dermal fibroblasts and attenuates…
Abstract Number: 2071 • 2016 ACR/ARHP Annual Meeting
Expression of Neuraminidase 1 (NEU1) Is Upregulated in the Lungs of Scleroderma Patients with Pulmonary Fibrosis, and Gene Delivery of NEU1 to Mouse Lungs Elicits Accumulation of CD8+ Lymphocytes and Collagen
Irina G. Luzina^1,2, Anne E. Wyman^1,2, Virginia Lockatell², Zahid Noor², Nevins W. Todd^1,2, Simeon E. Goldblum^1,2 and Sergei P. Atamas^1,2, ¹Baltimore VA Medical Center, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: We and others have previously reported that pulmonary fibrosis in patients with scleroderma is accompanied by pulmonary accumulation of predominantly CD8+ T lymphocytes. Earlier…
Abstract Number: 2072 • 2016 ACR/ARHP Annual Meeting
Fli1-Haploinsufficient Dermal Fibroblasts Promote Skin-Localized Transdifferentiation of Th2- and Th17-like Regulatory T Cells
Ryosuke Saigusa¹, Yoshihide Asano², Takuya Miyagawa², Megumi Hirabayashi², Kouki Nakamura¹, Shunsuke Miura³, Takashi Yamashita², Yohei Ichimura¹, Takehiro Takahashi¹, Tetsuo Toyama², Takashi Taniguchi¹, Ayumi Yoshizaki², Maria Trojanowska⁴ and Shinichi Sato¹, ¹Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ³University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁴Arthritis Center, Boston University, Arthritis Center, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a multisystem connective tissue disease characterized by autoimmunity/inflammation, vasculopathy, and tissue fibrosis. Fli1 is a member of Ets family transcription…
Abstract Number: 2155 • 2016 ACR/ARHP Annual Meeting
Crosstalk Between IL-6 and TNF-Alpha Signaling Pathway in Rheumatoid Arthritis Synovial Fibroblasts
Alvaro Valin¹, Yolanda Ruano², Manuel J. Del Rey³, Carmen M. García-Herrero³, Eduardo Martín-Guerrero¹, Beatriz Bravo⁴, Juan D. Cañete⁵, José L. Rodríguez-Peralto² and Jose L. Pablos^3,6, ¹Grupo de Enfermedades Inflamatorias y Autoimmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ²Pathology Department, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ³Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁴Servicio de Traumatología y Cirugía Ortopédica, Hospital 12 de Octubre, Madrid, Spain, ⁵Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁶Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: Although elevated IL-6 and its soluble receptor (sIL6R) have been found in the serum and synovium of arthritic patients, the molecular mechanisms by which…

« Previous Page
1
…
3
4
5
6
7
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.